Abstract
Infantile hemangiomas (IHs) are common benign vascular tumours in infants (estimated prevalence 5% to 10%).1 Oral propranolol is currently the first-line treatment for complicated proliferative IHs.2 It is approved by the US Food and Drug Administration and the European Medicines Agency for treating complicated IHs, but questions remain regarding the optimal modalities of use.3 We conducted an international survey to assess practices in prescribing oral propranolol for IHs among practitioners dealing with IHs worldwide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
